Bing Zheng
24Patents
8h-index
17Co-inventors
68Inventor score
Filing activity: Jul 15, 2008 → Apr 19, 2021
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US8545850B2 | Anti-CD79B antibodies and immunoconjugates and methods of use | Emerging Cross-Sectional Technologies | 37 | Active |
| US8088378B2 | Anti-CD79B antibodies and immunoconjugates and methods of use | Emerging Cross-Sectional Technologies | 29 | Active |
| US9845355B2 | Humanized anti-CD79b antibodies and immunoconjugates and methods of use | Emerging Cross-Sectional Technologies | 19 | Active |
| US8691531B2 | Anti-CD79B antibodies and immunoconjugates and methods of use | Emerging Cross-Sectional Technologies | 18 | Active |
| US9896506B2 | Anti-CD79B antibodies and immunoconjugates and methods of use | Emerging Cross-Sectional Technologies | 18 | Active |
| US8362213B2 | Anti-FcRH5 antibodies and immunoconjugates and methods of use | Chemistry; Metallurgy | 17 | Active |
| US8466260B2 | Anti-FcRH5 antibodies and immunoconjugates and methods of use | Emerging Cross-Sectional Technologies | 15 | Active |
| US8617559B2 | Anti-FcRH5 antibodies and immunoconjugates and methods of use | Chemistry; Metallurgy | 14 | Active |
| US9360484B2 | Anti-FcRH5 antibodies and immunoconjugates and methods of use | Emerging Cross-Sectional Technologies | 6 | Active |
| US9017951B2 | Anti-FcRH5 antibodies and immunoconjugates and methods of use | Chemistry; Metallurgy | 6 | Active |
| US10501545B2 | Anti-CLL-1 antibodies and methods of use | Chemistry; Metallurgy | 4 | Active |
| US10494432B2 | Anti-CD79B antibodies and immunoconjugates and methods of use | Emerging Cross-Sectional Technologies | 3 | Active |
| US10544218B2 | Anti-CD79B antibodies and immunoconjugates and methods of use | Emerging Cross-Sectional Technologies | 3 | Active |
| US10981987B2 | Humanized anti-CD79b antibodies and immunoconjugates and methods of use | Emerging Cross-Sectional Technologies | 3 | Active |
| USRE48558E1 | Anti-CD79B antibodies and immunoconjugates and methods of use | General | 2 | Active |
| US10239947B2 | Anti-CLL-1 antibodies and immunoconjugates | Physics | 1 | Active |
| US10227412B2 | Anti-CLL-1 antibodies and immunoconjugates | Physics | 1 | Active |
| US10266597B2 | Anti-CLL-1 antibodies and immunoconjugates | Physics | 1 | Active |
| US9751946B2 | Anti-CLL-1 antibodies and immunoconjugates | Physics | 1 | Active |
| US10639378B2 | Silvestrol antibody-drug conjugates and methods of use | Human Necessities | 1 | Active |
| US11466087B2 | Anti-CLL-1 antibodies and methods of use | Chemistry; Metallurgy | 0 | Active |
| US11866496B2 | Humanized anti-CD79B antibodies and immunoconjugates and methods of use | Emerging Cross-Sectional Technologies | 0 | Active |
| US11648315B2 | Silvestrol antibody-drug conjugates and methods of use | Human Necessities | 0 | Active |
| US11084877B2 | Anti-CLL-1 antibodies and immunoconjugates | Physics | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.